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Toll-like receptors in the pathogenesis of 
autoimmune diseases: recent and emerging 
translational developments
Laura Duffy 
Steven C O’Reilly
Immunology and Cell Biology Group, 
Faculty of Health and Life Sciences, 
Northumbria University, Newcastle 
upon Tyne, UK
Abstract: Autoinflammatory diseases are defined as the loss of self-tolerance in which an 
inflammatory response to self-antigens occurs, which are a significant global burden. Toll-like 
receptors are key pattern recognition receptors, which integrate signals leading to the activation of 
transcription factors and ultimately proinflammatory cytokines. Recently, it has become apparent 
that these are at the nexus of autoinflammatory diseases making them viable and attractive drug 
targets. The aim of this review was to evaluate the role of innate immunity in autoinflammatory 
conditions alongside the role of negative regulation while suggesting possible therapeutic targets.
Keywords: autoimmunity, toll-like receptors, danger signals, arthritis
Introduction
The innate immune system serves as the first line of defense in tackling host invasion, 
recognizing highly conserved pathogenic-associated molecular patterns (PAMPs) found 
on invading organisms. Subsequent signaling allows the host to mount an immune 
response without memory. The innate immune system uses a diverse set of pattern 
recognition receptors (PRRs) to sense the intra- and extracellular environment for 
pathogens.1 Toll-like receptors (TLRs) are PRRs that play a key role in the recogni-
tion of PAMPs, in the initiation of the hosts’ immune response, and interestingly, in 
neurological development2 and are conserved in species ranging from worms to mam-
mals, denoting their importance.3 The basic structure of mammalian TLRs consists of 
a leucine-rich repeat extracellular domain, which creates a horseshoe-like solenoid 
capable of interacting with ligands, and the cytoplasmic toll/interleukin (IL)-1 receptor 
domain, associated with the TLR signaling cascade, culminating in nuclear factor kappa 
B (NF-kB) translocation.4,5 Along with NF-kB, TLRs also activate activator protein 1 
(AP-1) and interferon regulatory factors (IRFs), such as IRF3 and IRF7; both of these 
cascades lead to the production of cytokines and pro- and antiinflammatory media-
tors, which are critical in mounting the host response (Figure 1). There are ten known 
TLRs in humans, residing on the cell surface to interact with pathogenic ligands or 
intracellularly in endosomes to interact with pathogenic nucleic acids (Figure 1). TLRs 
also respond to damage-associated molecular patterns (DAMPs) that are endogenous 
ligands released at the site of tissue damage (Table 1).
Autoimmune diseases encompass a wide range of diseases, which can affect a 
single organ to the whole organ systems. Autoimmune diseases are generally defined 
as the dysregulation of the immune system causing an immune response to “self ”. The 
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etiology of autoimmunity is still a widely debated topic with 
some claiming environmental factors play a large role in its 
development,6 while others claiming genetics play the lead 
role. However, it is generally accepted that it is an interplay 
between genetic and environmental factors that lead to the 
development of autoimmunity. Although not fully understood, 
TLRs have been implicated in the pathogenesis of various 
autoimmune diseases such as rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE), and systemic sclerosis 
(SSc).7–9 The aims of this review were to highlight the roles 
of TLRs in autoimmune diseases, particularly in rheumatic 
diseases, and to suggest where these can be targeted for 
therapeutic intervention and treatment. Finally, further areas 
of study of the TLRs in relation to autoinflammatory condi-
tions have been suggested.
Table 1 Endogenous ligands of human TLRs
TLR Endogenous ligand
TLR1 –
TLR2 Serum amyloid A, snapin A, HMGB-1, biglycan, endoplasmin, 
hyaluronan, and monosodium urate crystals
TLR3 mRNA
TLR4 S100A8/9, tenascin C, surfactant protein A, high-mobility group 
box protein 1, fibrinogen, heat shock proteins (-20, -60, -70, 
and -96), extra domain A of fibronectin, biglycan, CD138, 
β-defensin, heparan sulfate, and resistin
TLR5 –
TLR6 Heat shock proteins (-60, -70, and -96) and soluble 
tuberculosis factor 
TLR7 ssRNA-containing ICs, siRNA
TLR8 ssRNA-containing ICs, human cardiac myosin 
TLR9 DNA-containing ICs
Note: “-’’, no known endogenous ligand.
Abbreviations: ICs, immune complexes; HMGB-1, high mobility group box 1; 
siRNA, small interfering RNA; ssRNA, single-stranded RNA; TLR, toll-like receptor.
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Figure 1 Basic signaling of TLRs: upon ligation with their associated ligands (common ones are shown in red), TLRs form homo- or heterodimers.
Notes: Following ligation, TIR domains engage with adaptor proteins. TLRs 1, 2, 5, 6, 7, 8, 9 signal via the TIR domain-containing adaptor protein MyD88, while TLR3 uses 
the TRIF. TLR4 can move from the plasma membrane in order to switch signaling from MyD88 to TRIF, with the use of TRAM. A complex cascade, involving molecules such 
as IRAK-1, results in the induction of key transcription factors such as NF-kB. ‘’?’’, unknown.
Abbreviations: dsRNA, double-stranded RNA; IFNβ, interferon-β; IL, interleukin; IRAK-1, IL-1R-associated kinases; IRF, interferon regulatory factor; LPS, lipopolysaccharide; 
NF-kB, nuclear factor kappa B; TIR, toll IL-1 resistance; ssRNA, single-stranded RNA; TLR, toll-like receptor; TRAM, TRIF-related adapt molecule; TRIF, TIR-domain-
containing adaptor protein-inducing IFNβ.
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TLRs in RA
RA is an autoimmune disease, which primarily affects 
the synovial joints, causing chronic inflammation leading 
to the destruction of articular tissues. RA affects ~1% of 
the population. The exact molecular pathogenesis of the 
disease remains unclear; however, it is widely accepted 
that the activation of synovial fibroblasts, by self-reactive 
immune cells, causes inflammation, which is a critical step 
in disease pathogenesis. Synovial inflammation and conse-
quent destruction are mediated via an increased expression 
of inflammatory cytokines and matrix metalloproteinases 
(MMPs). Elevated levels of TLRs and their associated 
endogenous ligands have been shown to contribute to the 
pathogenesis of the disease.10,11
The events leading to the activation of TLRs in RA are 
still a discussed topic; the ligands associated with septic 
inflammation are less clear than their exogenous  counterparts. 
It is believed that PAMPs, derived from commensal flora or 
infectious bacteria, are involved in the initiation of RA.12 
Initial insult causes an autocrine loop involving increased 
MMPs, leading to increased damage (Figure 2). Intra-
articular injection of streptococcal cell wall fragments that 
contain TLR2 ligands induces an inflammation and arthritis 
that is MyD88 dependent. It has been revealed that DNA and 
peptidoglycans released from intestinal flora are present in the 
synovium of patients with RA,13 and oral microbiota may be 
important also. The presence of bacterial DNA, peptidogly-
cans, and lipopolysaccharides (LPSs) in the synovium will 
ultimately result in the activation of TLRs. Necrotic cells 
in the joints of patients suffering from RA have also been 
shown to activate TLR3 through the release of endogenous 
RNA.14 The release of single-stranded RNA (ssRNA) from 
the patient’s cell  during cellular stress or injury can activate 
TLR8 in the synovial fluid.15 Recently, IL-29, released early 
in viral infection, has been shown to affect the release of 
TLR-mediated cytokines and TLR expression, possibly 
contributing to disease progression.16 It has been found that 
several endogenous ligands, such as high mobility group 
box 1 (HMGB-1), are released from damaged cells or induced 
in the synovial tissue of patients with RA.17–19 HMGB is a 
nuclear architectural protein and an endogenous TLR4 ligand; 
HMGB-1 and S100-A8 levels are increased in patients with 
RA20. In combination, these studies show the complexity 
and various systems that may be involved in initiating and 
maintaining RA.
TLR4 is important in the pathogenesis of RA, as shown 
by enhanced expression in the synovial tissue of patients 
with RA and protection from experimental models of RA in 
TLR4 knockout mice.21,22 TLR signaling has been implicated 
in an indirect mechanism of inducing inflammation via the 
protein kinase inositol-requiring enzyme 1α (IRE1α).23 
Active IRE1α unconventionally splices Xbox-binding pro-
tein 1 (XBP1).24 Interestingly, sXBP1 encodes an enhanced 
transcription factor involved in the expression of proinflam-
matory molecules, such as tumor necrosis factor (TNF)-α and 
IL-6. Increased sXBP1, mediated by the TLR activation of 
IRE1α, can increase proinflammatory molecules contributing 
to inflammation in patients with RA.
Figure 2 Role of TLRs in RA joint damage: initial cellular damage causes the release of DAMPs that are upregulated during inflammation, possibly caused by PAMPs.
Notes: Consequent TLR activation on cells residing in the synovium results in increased production of key inflammatory cytokines such as TNF-α and IL-1, which in turn can 
activate FLS, leading to increased MMPs. Increased MMPs lead to the loss of homeostasis between TIMPs and MMPs leading to increased destruction of ECM and cartilage, 
causing the release of DAMPs and activation of TLRs on FLS.
Abbreviations: DAMPs, damage-associated molecular patterns; ECM, extracellular matrix; FLS, fibroblast-like synoviocytes; HMGB-1, high-mobility group box 1; IL, 
interleukin; INF, interferon; miRNA, microRNA; MMPs, matrix metalloproteinases; PAMPs, pathogenic-associated molecular patterns; RA, rheumatoid arthritis; TIMPs, tissue 
inhibitor of metalloproteinases; TLR, toll-like receptor; TNF-α, tumor necrosis factor-α.
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The presence of unfolded proteins in the lumen of 
the endoplasmic reticulum activates the unfolded protein 
response (UPR) pathway. The UPR pathway is a highly con-
served mechanism, which leads to the activation of IRE1α. 
The translation of IRE1α is comparable in patients with RA 
and osteoarthritis, meaning that the expression between 
the two diseases is unchanged. However, the detection of 
mRNA coding for sXBP1 is increased only in patients with 
RA. As IRE1α exclusively splices XBP1, the study showed 
that it is the activation, not the expression, of IRE1α which 
is altered between the diseases.23 An in vivo mouse model 
of RA found that the deletion of IRE1α, in myeloid cells, 
delayed the onset and severity of the disease.23 The role 
of sXBP1 was further clarified when it was found that the 
activation of IRE1α was uncoupled from the UPR pathways 
in patients with RA. Another study found the secretion of 
TNF-α was not only was induced by sXBP1, but TNF-
α-induced sXBP1 expression, was even more prominent 
when combined with IL-6 and IL-1β.25 From a therapeutic 
standpoint, targeting TLR-dependent IRE1α or TNF-α 
could disrupt the autocrine loop described by reducing 
sXBP1 expression and in turn reducing the expression of 
proinflammatory cytokines.
The hampering of effective therapies to combat RA is 
largely due to an incomplete knowledge of the endogenous 
ligands associated with chronic “sterile” inflammation. TLR4 
signaling is associated with the exogenous ligand LPS; how-
ever, the activation of TLR4 signaling has also been shown via 
the endogenous ligand tenascin C. Tenascin C is not usually 
produced in adult tissue but is transiently expressed upon tis-
sue injury or persistently expressed in chronic inflammation. 
Interestingly, the domains within tenascin C share homology 
with those found in DAMPs, which is associated with TLR 
signaling. Wild-type and TenC-/- mice have been used to dissect 
tenascin C’s role in TLR signaling. It was found that tenascin 
C plays a part in the maintenance of inflammation, more 
specifically its fibrinogen-like globe domain.26 The challenge 
experienced with wild-type mice with recombinant fibrinogen-
like globe was dose-dependent stimulation of inflammation, 
which required functioning MyD88 and is dependent on 
TLR4.26 Once inflammation is initiated, tenascin C acts in a 
destructive cycle by amplifying the inflammatory response 
and inducing other endogenous proinflammatory molecules.
Unlike tenascin C, the IL-17-IL-23 axis has been shown 
to be important in both the onset phase and destruction phase 
of RA. The axis can also be linked to the expression of key 
TLRs such as TLR2, TLR3, and TLR4 in fibroblast-like 
synoviocytes, which are obtained from patients with RA. 
Of therapeutic importance is the inhibition of the STAT3 
pathway, which has been shown to reduce the expression of 
TLR3 in fibroblast-like synoviocytes.27 It has also been sug-
gested that TLR3 expression is increased in the onset stage of 
RA.28 A research group has documented a role for microRNA 
(miRNA)-26a to downregulate TLR3 production,29 which 
could act as a possible therapeutic agent for the treatment of 
RA and other inflammatory diseases associated with TLR 
signaling. In these studies, repression of TLR signaling via 
targeting of their ligands or downstream mediators has been 
useful over direct targeting of TLR themselves, which are 
essential for immunity. Nonspecific targeting of TLRs, and 
indeed their downstream mediators, will leave the patient 
open to invasion via pathogenic organisms. However, gen-
eralized inhibition may be overcome due to a high degree 
of cross talk between TLR-initiated signaling pathways. For 
example, patients with defunct MyD88 are usually resistant 
to common bacterial and fungal infection, meaning that the 
repression of this key molecule does not leave the patient 
completely immunocompromised.30 It is also important to 
note that protective roles of TLRs have been defined, such 
as TLR9 in SLE, and that increased levels of other TLRs 
in autoimmunity may be to offer a protective role; thus, 
complete inhibition would be counterintuitive. In the case 
of autoimmunity, it is rather the overzealous activity of 
TLRs causing damage. TLRs also regulate each other, for 
example, TLR9 regulates TLR7; thus any therapeutic agent 
should not completely inhibit TLR signaling but rather the 
increased activity.
A novel role for TLR5 in RA has recently been detailed.31 
The study found that TLR5 expression was higher in mac-
rophages and epithelial cells derived from the lining and 
sublining of synovial tissue were obtained from patients 
with RA, when compared to the control.31 More importantly, 
it was found that not only TLR5 regulated TNF-α in RA 
monocytes but also the expression levels of TLR5 strongly 
correlated with TNF-α production and the disease sever-
ity score.31 Therefore, effective targeting of TLR5 has the 
potential to decrease the expression of TNF-α and lower the 
disease severity score.
Endosomal TLRs (3, 7, 8, and 9; Figure 1) have been 
implicated in RA progression. TLRs 7 and 8 respond to 
ssRNA. Genetic deletion of murine TLR7, which is compa-
rable to human TLR8 (huTLR8), has been shown to decrease 
RA disease parameters, such as inflammation.32 Accurate 
murine models of TLR8 have proven somewhat difficult 
as murine TLR8 does not recognize the same ligands as 
huTLR8 due to a sequence difference of five amino acids. 
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However, this has been addressed with the production of 
huTLR8-expressing mice; this development will allow fur-
ther research into the exact role of huTLR8 in RA. Genera-
tion of the mice was not trivial; mice that were expressing 
high levels of huTLR8 had a shorter life span than those 
expressing low levels of huTLR8.33 Development of the 
mice led to the suggestion that TLR8 may be implicated in 
the maintenance and not the onset of the disease, acting after 
ligation with “self ” ssRNA, which was released after initial 
damage. Thus, therapeutic targeting of TLR8 may be useful 
in patients with chronic RA. In support of the role of TLRs 
and downstream interferon induction, a polymorphism has 
been described in IRF5.34
TLRs in SLE
SLE has various pathogenic factors leading to an array of 
clinical manifestations across multiple organs. Autoantibod-
ies, produced by hyperactive B-cells, are often found against 
double-stranded DNA and/or DNA/RNA-bound proteins 
and appear to play a crucial role in the disease, although the 
molecular mechanisms remain elusive. The autoantibodies 
are both diagnostic and pathologic in the disease, and the 
disease is characterized by a high type I interferon. The 
clearance of apoptotic cells in patients with SLE is deficient; 
this can result in the formation of the immune complex 
(IC). The structural and sequential similarity of “self ” and 
microbial nucleic acids can result in the binding of “self ” 
DNA to anti-DNA antibodies; this recognition will form an 
IC (DNA and anti-DNA antibody). The IC can interact with 
TLR9 resulting in dendritic cell activation, consequently 
activating B- and T-cells to release proinflammatory cyto-
kines, ultimately resulting in inflammation.7 Conflicting 
studies have been reported about the role of TLR9 in SLE, 
with some claiming TLR9 has a protective or regulatory 
role, and it is in fact TLR7 that enhances the autoimmune 
response.35,36 The ambiguity surrounding TLR9 may be in 
part due to the methylation of mammalian DNA that may 
not be recognized by TLR9. These contradictory reports 
should be considered in terms of the murine models used as 
they differ between studies; also, the exact molecular detail 
of the protective response needs to be properly detailed. In 
contrast to TLR9, the role of TLR7 in SLE appears to be 
proinflammatory and may also be regulated by TLR9 itself.37 
The activation of TLR7 in plasmacytoid dendritic cells (pDC) 
can be caused by decreased clearance or increased number of 
autoantibodies that misdirect self RNA to the pDC to activate 
TLR7 and elicit an immune response. It is hypothesized that 
TLR9 interacts with TLR7 in the endosome inhibiting its 
response;35 this has the potential to explain the increase in 
disease in TL9-/- murine models.
The mechanism by which TLR7 and TLR9 translocate to 
endosomes has recently been suggested to be dependent on 
heat shock protein 90 (HSP90).38 The study found that the 
inhibition of HSP90 alleviated the disease activity in murine 
models.38 Thus, targeting of HSP90 may be of therapeutic 
benefit. Although there are reports of reduced clearance 
of apoptotic cells in SLE and that this may be the stimulus 
for the autoantibodies, precisely which cells are apoptotic 
is unclear. It has recently been found that RNA complexes 
containing antimicrobial peptides trigger TLR7- and TLR8-
mediated inflammation in dendritic cells.39 It is now known 
that this is due to neutrophil extracellular traps (NETs); that 
it is neutrophils releasing DNA (nuclear and mitochondrial) 
in a net type fashion in a controlled cell death manor. NETs 
contain antimicrobial peptides and may be a host response, 
but patients with SLE trigger an immune response via den-
dritic cells via TLR9 activation. Interestingly SLE patients’ 
neutrophils released more NETs on stimulation than healthy 
controls.40 Furthermore, patients with SLE have a reduced 
ability to degrade NETs.41
The sex bias in SLE has been well documented, with an 
array of possible causes. Gene analyses of peripheral blood 
mononuclear cells treated with 17β-estradiol (E2) increased 
the secretion of key proinflammatory cytokines as well as gene 
expression of TLR8 mediated through estrogen receptor alpha. 
In fact, the expressions of all of the endosomal TLRs were 
increased upon treatment with E2.42 Further work on the exact 
TLR response to estrogen may produce a viable therapeutic 
target for SLE, alongside a molecular justification for sex bias.
TLRs in SSc
SSc is an autoimmune idiopathic connective tissue disease, 
which has three clearly defined hallmarks: small vessel 
vasculopathy, production of autoantibodies, and fibroblast 
dysfunction leading to increased collagen accumulating in 
the skin and major organs.43
The symptoms of SSc are mainly caused by the deposi-
tion of excess extracellular matrix (ECM), which is seen 
when MMPs and their inhibitors, such as tissue inhibitor of 
metalloproteinases (TIMP-1), lose homeostasis. Circulat-
ing monocytes play an important role in the development of 
SSc, and a link has been shown between TLR8 signaling and 
excessive TIMP-1 production in these cells.44 Monocytes are 
also found in close proximity to myofibroblasts.
It has also recently been found that the AP-1 family mem-
ber, Fos-related antigen 2 (Fra2), facilitates TLR8-mediated 
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overexpression of TIMP-1, in ex vivo monocytes derived 
from patients with SSc.45 Skin-infiltrating monocytes from 
patients with SSc showed an increase in Fra2; treatment of 
these monocytes with a histone demethylation agent caused an 
increase in both Fra2 and TIMP-1 production when challenged 
with the TLR8 agonist ssRNA; and increased TIMP-1 can 
directly induce myofibroblast transdifferentiation.45 The fac-
tors affecting transdifferentiation of myofibroblast is complex; 
once transdifferentiation is complete, the myofibroblasts are 
able to upregulate the expression of many fibrotic proteins, 
such as collagen 1. The revealing of the transdifferentiation 
pathway, involving Fra2 and TLR8, may evoke further study 
into the epigenetic regulation involved in myofibroblast 
transdifferentiation. The TLR8-mediated induction of TIMP-1 
and the subsequent fibrosis, while important in revealing 
mechanisms, does not clarify where the ssRNA is derived. 
Synthetic ssRNA was used to stimulate cells, but incubation of 
monocytes with the serum of patients diluted in media incited 
the same response as the synthetic RNA ligand and this could 
be blocked by the treatment of the serum with RNAase; thus, 
patients have elevated ssRNA in their circulation. It is specu-
lated but not proved that this is from damaged endothelium.
DAMPs associated with SSc include ligands for TLR4, 
both of which are elevated in SSc skin and lung tissue.46 The 
endogenous ligands for TLR4 can be released as the conse-
quence of cellular stress or damage, oxidative stress, and 
ECM remodeling. Stimulation of TLR4 in healthy fibroblasts 
was associated with the induction of genes linked with ECM 
remodeling. Although TLR4 signaling in SSc is complex, 
it is believed that enhanced Smad signaling, downregula-
tion of TGF-β antagonist, and suppression of anti-fibrotic 
miRNAs lead to prolonged fibroblast activity,46 resulting in 
pathological fibrosis. Murine models also show that a point 
mutation in the TLR4 gene attenuated bleomycin-induced 
skin fibrosis.47 The exact mechanism for the attenuation in the 
murine model remains uncertain; however, the model clarified 
the pivotal role of TLR4 in the development of the disease. 
It has recently been demonstrated that TLR4 induction of 
fibrosis in the bleomycin model is mediated via IRF5. In this 
paradigm, the activation of IRF5 via TLR4 ligation through 
the standard MyD88 signaling pathway leads to the activa-
tion of fibrosis-related genes as IRF KO mice are protected 
and IRF-/- fibroblasts are anti-fibrotic; of interest is the fact 
that immune abnormalities are absent in the IRF KO mice 
including B-cell activation reductions and IL-6 levels; it is 
this loss of IL-6 induction that is important here.48,49
The exact molecular initiation of SSc remains unknown; 
however, it is believed that disruption in the vasculature 
leads to epithelial damage. This damage in turn can release 
“danger” molecules such as serum amyloid A.50 In dermal 
fibroblasts, TLR2 plays a role in enhancing the signal pro-
duced by serum amyloid A in order to secrete proinflamma-
tory cytokines such as IL-6; this system is dependent on the 
downstream molecule IRAK4. Therefore, targeting of TLR2 
may be of therapeutic benefit. Interestingly, it has also been 
suggested that infection with Epstein–Barr virus may cause 
a patho-immunological response in patients with SSc and 
contribute to fibrosis via aberrant TLR7 and TLR9 signal-
ing.51 It has also been found that NF-kB regulates epidermal 
homeostasis and can promote fibrosis in in vivo models.52
Cross talk between the complex pathways involved in 
fibrosis is poorly understood; the roles TLRs play in the 
sustained expression of profibrotic molecules, as well as the 
transdifferentiation of myofibroblasts, appear to be pivotal 
and may open up new therapeutic options for a disease with 
little available therapy. In addition, is there a hierarchy among 
DAMPs?
TLRs in Sjogren’s syndrome
Sjogren’s syndrome (SS) is an autoimmune disorder in which 
the immune system attacks fluid-secreting glands, for exam-
ple, the lacrimal and salivary glands, causing hypofunction 
that leads to dry eyes and dry mouth (xerostomia). There is a 
lymphocytic infiltrate in the glands leading to destruction and 
also autoantibodies, implying a role of the adaptive immune 
system, but the innate immune system may also have a role 
to play. In support of this hypothesis, it has been shown that 
salivary epithelial gland cells (line the glands) from patients 
with SS have higher levels of TLR expression compared to 
controls,53 and secretion of cytokines, from B-cells, increased 
upon TLR7 and TLR9 stimulation in primary SS.53,54
Interestingly, there is an increased occurrence of glandular 
destruction that could be releasing endogenous TLR ligands 
(DAMPs). In support of this hypothesis, it was shown that 
mouse glandular cells express TLR3 and that the injection 
of TLR3 ligand directly induces salivary gland hypofunc-
tion and that this was reversible on the cessation of TLR3 
ligand, suggesting that it is independent of autoantibody 
production.55 This was followed up with another study dem-
onstrating reduced salivary flow in PolyI:C-treated mice.56 
TLR9 is also elevated in SS and promotes B-cell germinal 
center formation.57
Impaired phagocytosis of apoptotic salivary epithelial 
cells by monocytes has been reported in patients with SS, thus 
indicating that if increased apoptosis and reduced clearance 
are occurring this would lead to elevated concentrations of 
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antigenic nucleic acids.58 Interestingly, the microRNA146a is 
dysregulated in SS compared to controls; one of the targets 
of miR146a is IRAK, which is a critical component in TLR 
signaling.59
TLRs in myositis
Myositis is a chronic inflammatory autoimmune disorder, 
consisting of five conditions that primarily affects skeletal 
muscles, causing profound muscle weakness and fatigue 
(Figure 3). There is a presence of an immune cell infiltration; 
however, this does not always correlate with disease. Incu-
bation of skeletal muscle fibers with the DAMP HMGB-1 
results in robust induction of MHC class I expression, which 
is a histopathological hallmark of myositis. The incubation of 
isolated muscle fibers with HMGB-1 also resulted in reduced 
intracellular calcium levels.60
It was further demonstrated that the receptor needed for 
HMGB-1-induced muscle dysfunction was TLR4, and not 
RAGE receptor, and that the induction of the muscle dysregu-
lation HMGB-1 was dependent on its redox state.61 In addi-
tion, the treatment of patients with corticosteroids reduced 
the aberrant HMGB-1 expression in myositis. Stimulation of 
isolated myotubes with the TLR3 ligand, poly I–C, resulted 
in the production of interferons, which subsequently leads 
to the upregulation of MHC class I, the hallmark of myosi-
tis.62 TLR3, TLR7, and TLR9 have also been demonstrated 
to be upregulated in myositis tissue.63 Interestingly, TLR7 
stimulation in combination with antigen-expressing apoptotic 
myoblasts in a mouse model, but not TLR7 stimulation alone, 
resulted in autoantibody production and replicated histo-
pathological findings in human myositis.64 TLR3 and RIG-I 
have also been recently demonstrated to be upregulated in 
Figure 3 Basic role of TLRs in myositis: post tissue damage (eg, via infection or exercise), cells release DAMPs.
Notes: These DAMPs ligate to TLRs on infiltrating cells such as macrophages and plasmacytoid cells. The ligation ultimately results in the secretion of proinflammatory 
molecules into the microenvironment. IL-1 binds to its receptor, IL-1R, and exerts its downstream effects, which lead to capillary loss and hypoxia. The damage to the cells 
caused by the cytokine, in turn, produces more DAMPs that can bind to the TLR and induce further inflammation and increase chemokine release in the muscle fibers. Recent 
murine models of myositis have shown the importance of TLR8, MyD88, and NF-kB in the development of myositis.84 Possible dysregulation of miRNA and long noncoding 
RNAs and altered inflammation resolution also contribute.
Abbreviations: DAMPs, damage-associated molecular patterns; ECM, extracellular matrix; FLS, fibroblast-like synoviocytes; IL, interleukin; miRNA, microRNA; MMPs, 
matrix metalloproteinases; NF-kB, nuclear factor kappa B; TLR, toll-like receptor; TNF-α, tumor necrosis factor-α.
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myositis tissue.65 The link between inflammation and clini-
cal course in myositis is not linear, and much more work is 
required to dissect the role of innate immunity in the disease.
TLRs in other autoimmune diseases
TLRs are also implicated in an abundance of other autoim-
mune diseases, such as inflammatory bowel disease (IBD), 
multiple sclerosis, and diabetes mellitus (Table 2).
In healthy conditions, the expression of TLRs in the 
intestinal tract remains low in order to reduce the recogni-
tion of the commensal intestinal flora.66 However, it has 
been shown in pediatric IBD samples that mRNA levels 
of TLR4 and TLR2 are increased in comparison with their 
non-inflamed counterparts.67 Increased TLR expression will 
lead to increased TLR-mediated inflammation in the intes-
tines. As patients with IBD suffer from periodic injury and 
repair, it is of importance to understand the role of innate 
immunity. An in vivo model of TLR9-deficient mice found 
that deficient TLR9 leads to an increased susceptibility to 
intestinal damage and delayed healing, suggesting a regula-
tory role of TLR9.68
TLRs as therapeutic targets
The complex systems involved in TLR signaling and their 
pivotal role in autoimmunity remain incompletely under-
stood; despite this, TLRs and their associated pathways 
remain a key therapeutic target.
Inhibitory oligodeoxynucleotides (ODN) were originally 
shown to inhibit TLR9 signaling, using B-cells and pDC 
from patients with SLE.69 It was found that ODN IRS954 
inhibited the cells response, measured via autoantibody lev-
els, to synthetic and exogenous TLR7 and TLR9 ligands.70 
However, it has recently been shown that a single ODN, 
ODN 1411, can inhibit all of the endosomal TLRs (3, 7, 8, 
and 9) in primary human cells.71 The exact mechanism of the 
ODNs inhibition in TLR is yet to be discovered with some 
stating extracellular domain binding,71 while others claiming 
it exerts its effects to disrupt downstream molecules, such as 
HMGB.72 The study, involving the endosomal TLRs, found it 
was most likely ODN1411 was acting via direct interaction 
with the endosomal TLRs that elicited the inhibitory effect.71 
Overall, the development of ODNs has the potential to be of 
benefit in both RA and SLE.
The inhibitor of salt-inducible kinase (SIK), HG-9-9101, 
has been shown to significantly reduce TLR4- and TLR2-
induced TNF-α production in human myeloid cells, while 
also increasing the secretion of the anti-inflammatory mol-
ecule IL-10.73 Interestingly, data presented found that SIK 
inhibition did not fully suppress the immune system;73 this 
has clinical relevance as the treatment with the SIK inhibitor 
would not leave the patient completely immunocompromised.
An alternative to novel drug development is the use of a 
compound already available for other diseases; an example of 
this is mianserin. Mianserin is a serotonin receptor antagonist, 
which is usually delivered as an antidepressant. It was found 
that mianserin was able to not only inhibit endosomal TLRs 
in primary human cells but also reduce spontaneous TNF and 
IL-6 production in synovial membrane cultures.15 A further 
study used the collagen-induced arthritis (CIA) murine model 
to confirm that mianserin was able to decrease RA disease 
progression and preserve joint architecture.32 The effect of 
mianserin, on TLRs, was only elicited at a dose that would 
be unsafe in humans, limiting its use. An extension of this 
work found that fluoxetine, a selective serotonin reuptake 
inhibitor was able to reduce inflammation and bone erosion 
in CIA murine model and also reduce spontaneous cytokine 
production in human RA synovial membrane cultures.74 
Although the use of selective serotonin reuptake inhibitor 
appears to hold promise, it is important to note that their 
effects on TLRs is an off-target effect and further research 
would be required before the treatment could be delivered 
to patients suffering from RA.
Table 2 Variety of some TLRs implicated in autoimmune diseases
TLR TLRs implicated in pathogenesis
TLR1 TLR2 TLR3 TLR4 TLR5 TLR6 TLR7 TLR8 TLR9 TLR10
RA ü ü ü ü ü ü
SLE ü ü
SSc ü ü ü ü ü
SS ü ü
Myositis ü ü ü ü
Multiple sclerosis 
IBD ü ü ü
Diabetes mellitus 
Abbreviations: IBD, inflammatory bowel disease; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjogren’s syndrome; SSc, systemic sclerosis; TLR, toll-
like receptor.
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As mentioned earlier, targeting of associated molecules 
such as IRE1α may also hold therapeutic potential. A study 
found that 7-hydroxy-4-methylcoumarin (4µ8C) was a novel 
inhibitor of IRE1α.75 A further in vivo study found that 4µ8C 
was able to inhibit IRE1α, along with a significant reduction 
in TNF-α and IL-6 in the joint tissue of 4µ8C-treated mice.23 
This could hold potential in the treatment of RA.
The development of OPN-305, a humanized IgG4 mono-
clonal antibody, by Opsona Therapeutics also has potential 
benefits for patients with RA.76 OPN-305 targets TLR2, 
possibly via binding to ligand sites resulting in an inability 
to heterodimeric with TLR1 or TLR6. The first in-human 
Phase I study showed promising results;77 even at the lowest 
dose (0.5 mg/kg), a 50% reduction in IL-6 was seen in ex 
vivo samples. Further ongoing studies are required to validate 
the use of OPN-305.
Although the targeting of TLRs is an exciting prospect, 
it is important to fully understand TLRs and their signaling 
pathways before the transfer can be made into clinics to treat 
autoimmune diseases.
Epigenetic regulation of TLRs
TLR signaling is critical in the immune host defense to 
pathogens and also to internal DAMPs, and thus tight regu-
lation of TLR signaling must be in place to ensure a return 
to immune homeostasis and not unresolved inflammation. 
One mechanism of controlling TLR signaling is that of 
epigenetic regulation, specifically miRNAs. miRNAs are 
small, non-coding RNAs that regulate gene expression and 
are mainly synthesized by RNA polymerase II. miRNAs 
work by imperfectly binding the 3′ untranslated region of 
target mRNAs and downregulating their expression through 
mRNA degradation or mRNA decay. Many miRNAs are 
induced rapidly after the activation of TLR. One of the most 
important and first to be described to negatively regulate 
TLR signaling was miR 155. miR155 is induced upon TLR4 
stimulation in macrophages78 and is also regulated by TLR3. 
miR155 is also dysregulated in arthritis, and miR155 KO 
mice are resistant to CIA.
Another hugely important miR in TLR signaling is 
miR146. MiR146a/b is upregulated in a TLR- and NF-KB-
dependent mechanism and targets TRAF6 and IRAK1: two 
key adaptor proteins in TLR signaling and proinflammatory 
cytokine production.79 Indeed, miR146a is critical in the 
resolution of inflammation in T-cells.80
In addition, miR21 has emerged as a key regulator of 
TLR signaling. It was found that upon TLR4 signaling that 
miR21 is induced; this binds to its cognate target, mRNA 
programmed cell death 4 (PDCD4) to reduce its expression. 
PDCD4 is a tumor-suppressor protein that regulates IL-10 
levels. Loss of PDCD4 in mice results in protection from 
LPS-induced lethality.81 PDCD4 is induced by inflammatory 
signaling and apoptotic debris. Because miR21 appears to 
be a critical regulator of TLR-negative signaling to restore 
immune homeostasis after stimulation, any disturbance in 
this may lead to exacerbated unrestrained inflammation. A 
recent manuscript has shown that unmanipulated levels of 
miR21 are reduced in RA patient’s immune cells (macro-
phages) and importantly, as opposed to control cells, the RA 
patients’ cells did not upregulate miR21 upon TLR stimu-
lation, suggesting an intrinsic defect. Interestingly, lower 
miR21 levels correlated with Th17 levels (Th17 cells are 
pathogenic in RA).82 An interesting question is whether the 
induced miRs to negatively regulate signaling are different 
in response to DAMPs and PAMPs, even though they signal 
through shared TLRs.
Modulation of miRNAs is now possible through both 
synthetic mimics and antagomirs, and this will alter the levels 
of the miRNAs and their targets. Enhancing the stability of 
the miRNAs is important in any therapeutic targeting, but 
it is likely this will happen and they could be key therapies 
in the future.
Conclusion
The innate immune system is a critical part of the response 
to pathogens, tissue damage, and the release of DAMPs. 
Chief among these systems are TLRs as part of the PRRs. 
TLRs sense pathogens and consequently activate NF-kB 
and inflammatory cytokines. However, an anti-inflammatory 
role has recently been described for TLR10.83 Resolution of 
inflammation and the return to homeostasis are important and 
these appear to be mediated, at least in part, by miRs that act 
to positively or negatively regulate inflammation. In autoin-
flammatory diseases such as RA, it may be that the feedback 
loop to restore homeostasis is somehow broken, and miRNA 
targeting with miR mimics may be one therapeutic option as 
these are chemically stable. Although TLRs and their associ-
ated ligands are an attractive target in the development of new 
therapies, we do not fully appreciate neither the complexity 
of signaling yet nor the full consequences of targeting TLRs 
and their signaling pathways. There are currently clinical 
trials underway in the use of endosomal TLR inhibitors that 
may be more valuable in rheumatic diseases. TLR-mediated 
inductions of miRNAs are now known to negatively regulate 
their signaling, and a greater understanding of the mechanism 
and targets of these miRNAs may yield new therapies.
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